Drug profile · INN
kanamycin sulfate
KANTREX
kanamycin sulfate (KANTREX) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — kanamycin sulfate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
kanamycin sulfate (KANTREX) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is kanamycin sulfate?
kanamycin sulfate (KANTREX) is a bacterial 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for kanamycin sulfate?
KANTREX is a marketed brand name for kanamycin sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of kanamycin sulfate?
kanamycin sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.